Bauerova Katarina, Ponist Silvester, Navarova Jana, Dubnickova Martina, Paulovicova Ema, Pajtinka Martin, Kogan Grigorij, Mihalova Danica
Institute of Experimental Pharmacology, Slovak Academy of Sciences, Bratislava, Slovakia.
Neuro Endocrinol Lett. 2008 Oct;29(5):691-6.
The aim of this study was to evaluate the effects of a biological response modifier, glucomannan (GM), isolated from Candida utilis, on the progress of adjuvant arthritis in Lewis rats.
Adjuvant arthrithis was induced in Lewis rats by a single intradermal injection of Mycobacterium butyricum. GM was administered in two different doses of 5 and 7.5 mg/kg b.w. The treatment involved daily oral or intraperitoneal administration of the substance from day 0, i.e. the day of immunization to the end of the experiment - day 28. Cyclosporin A was used as a therapeutic standard in daily oral dose of 2.5 mg/kg b.w. The following parameters were monitored: hind paw volume, total antioxidant status, protein carbonyl groups, activity of N-acetyl-beta-D-glucosaminidase in plasma, lysozyme and peroxidase activity of peritoneal macrophages and activity of gamma-glutamyltransferase in homogenates of spleen, hind paw muscle and hind paw joint.
Beneficial action of GM was revealed mainly in hind paw volume decrease. Further decrease of the activity of the enzyme gamma glutamyltransferase (GGT) in the spleen, hind paw joint and muscle tissue homogenates, decrease of the plasmatic activity of N-acetyl-beta-D-glucosaminidase (NAGA), and finally suppression of lysozyme and peroxidase activity assessed in peritoneal macrophages were observed in arthritic animals treated with GM. All these findings speak in favor of the anti-inflammatory activity of glucomannan. Moreover, a significant improvement of the arthritis induced suppression of total antioxidant status and decrease of the level of the arthritis-associated protein carbonyls in plasma were detected.
The important characteristics of GM isolated from Candida utilis, such as good water solubility and relatively small molecular weight, along with the observed in vivo anti-inflammatory and antioxidant effects, appear to be promising features for its prospective use as a natural agent in prevention and supplementary therapy of rheumatoid arthritis.
本研究旨在评估从产朊假丝酵母中分离出的一种生物反应调节剂葡甘露聚糖（GM）对Lewis大鼠佐剂性关节炎进展的影响。
通过皮内单次注射丁酸分枝杆菌在Lewis大鼠中诱导佐剂性关节炎。GM以5和7.5mg/kg体重两种不同剂量给药。治疗从第0天（即免疫当天）开始，每日口服或腹腔注射该物质，直至实验结束——第28天。环孢素A作为治疗标准，每日口服剂量为2.5mg/kg体重。监测以下参数：后爪体积、总抗氧化状态、蛋白质羰基、血浆中N - 乙酰 - β - D - 氨基葡萄糖苷酶活性、腹膜巨噬细胞的溶菌酶和过氧化物酶活性以及脾脏、后爪肌肉和后爪关节匀浆中γ - 谷氨酰转移酶活性。
GM的有益作用主要表现为后爪体积减小。在用GM治疗的关节炎动物中，观察到脾脏、后爪关节和肌肉组织匀浆中γ - 谷氨酰转移酶（GGT）活性进一步降低，血浆中N - 乙酰 - β - D - 氨基葡萄糖苷酶（NAGA）活性降低，最后腹膜巨噬细胞中评估的溶菌酶和过氧化物酶活性受到抑制。所有这些发现都表明葡甘露聚糖具有抗炎活性。此外，还检测到关节炎诱导的总抗氧化状态抑制的显著改善以及血浆中与关节炎相关的蛋白质羰基水平的降低。
从产朊假丝酵母中分离出的GM的重要特性，如良好的水溶性和相对较小的分子量，以及观察到的体内抗炎和抗氧化作用，似乎使其有望作为一种天然药物用于类风湿性关节炎的预防和辅助治疗。
